生殖支原体经常与泌尿生殖道和直肠感染有关,随着大环内酯耐药和喹诺酮耐药生殖支原体感染的病例数持续增加。在这项研究中,我们检查了昆士兰州不同地理位置对这两种常见抗生素治疗的耐药性水平,澳大利亚。使用市售试剂盒(ResistancePlusMG;SpeeDx)筛选样品的大环内酯抗性相关突变,并通过PCR和DNA测序鉴定喹诺酮耐药相关突变。进行抗生素抗性突变和位置/性别之间的比较。在两个位置上,生殖支原体大环内酯的抗性水平都很高(62%)。在所有样本的10%中发现了喹诺酮耐药突变,许多样品带有突变,对大环内酯类和喹诺酮类均具有抗性。昆士兰州东南部的喹诺酮耐药性高于昆士兰州北部,这在男性和女性中都是一致的(P=0.007)。男性直肠拭子样本中的生殖支原体分离株对大环内酯(75.9%)和喹诺酮(19%)的耐药性很高,15.5%的人对这两类抗生素都有耐药性。总的来说,观察到的最低耐药水平是昆士兰州北部女性对喹诺酮类药物的耐药水平(1.6%).这些数据突出了昆士兰州内生殖支原体分离株的高水平抗生素耐药性,以及性传播感染临床医生在管理这些感染方面面临的挑战。数据确实如此,然而,表明同一州人群的抗生素耐药性水平可能不同,这对临床管理和治疗指南有影响。这些发现也支持需要持续的抗生素耐药性监测和定制治疗。
Mycoplasma genitalium is frequently associated with urogenital and rectal infections, with the number of cases of macrolide-resistant and
quinolone-resistant M. genitalium infection continuing to increase. In this study, we examined the levels of resistance to these two common antibiotic treatments in geographically distinct locations in Queensland, Australia. Samples were screened for macrolide resistance-associated mutations using a commercially available kit (ResistancePlus MG; SpeeDx), and
quinolone resistance-associated mutations were identified by PCR and DNA sequencing. Comparisons between antibiotic resistance mutations and location/gender were performed. The levels of M. genitalium macrolide resistance were high across both locations (62%).
Quinolone resistance mutations were found in ∼10% of all samples, with a number of samples harboring mutations conferring resistance to both macrolides and quinolones.
Quinolone resistance was higher in southeast Queensland than in north Queensland, and this was consistent in both males and females (P = 0.007). The M. genitalium isolates in rectal swab samples from males harbored high levels of macrolide (75.9%) and quinolone (19%) resistance, with 15.5% harboring resistance to both classes of antibiotics. Overall, the lowest observed level of resistance was to quinolones in females from north Queensland (1.6%). These data highlight the high levels of antibiotic resistance in M. genitalium isolates within Queensland and the challenges faced by sexually transmitted infection clinicians in managing these infections. The data do, however, show that the levels of antibiotic resistance may differ between populations within the same state, which has implications for clinical management and treatment
guidelines. These findings also support the need for ongoing antibiotic resistance surveillance and tailored treatment.